AD, The most common inflammatory skin disorder worldwide, is a highly heterogeneous condition with current treatments that do ...

The controversial biohacker has detailed his latest experiment in age reversal using full plasma replacement therapy.

Spravato is now the first-ever stand-alone therapy for treatment-resistant depression, and is on its way to becoming a ...

People with treatment-resistant depression can now take Spravato's ketamine-derived nasal spray as a standalone treatment.

Spravato is now the first stand-alone therapy for treatment-resistant depression, for patients who haven't responded to oral ...

The approval makes the treatment the first and only monotherapy for adults ... Also Read: Like Bristol-Myers Squibb And ...

Johnson & Johnson has achieved a significant milestone in depression treatment as the FDA granted expanded approval for Spravato as a monotherapy for treatment-resistant depression.

The announcement was welcome news for those with major depressive disorder, which affects an estimated 8.3% of the adult ...

CIII nasal spray, marking the first monotherapy to be approved for adults with treatment-resistant depression (TRD).